Two possible cases of erenumab‐induced xerostomia

What is known and objective Erenumab is a monoclonal antibody for the prophylactic treatment of migraine. We describe the first cases of xerostomia probably induced by this drug. Case summary We present two patients diagnosed with chronic migraine who started treatment with erenumab and presented wi...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical pharmacy and therapeutics Vol. 47; no. 6; pp. 824 - 825
Main Authors Selvi‐Sabater, Pablo, Carvajal‐Sanchez, Miguel Angel, Carrera‐Hueso, Francisco Javier
Format Journal Article
LanguageEnglish
Published England Hindawi Limited 01.06.2022
Subjects
adverse
dry
erenumab
Headache
Migraine
Monoclonal antibodies
Patients
Quality of life
Side effects
Xerostomia
dry
migraine
xerostomia
erenumab
adverse
Online AccessGet full text

Cover

More Information
Summary:What is known and objective Erenumab is a monoclonal antibody for the prophylactic treatment of migraine. We describe the first cases of xerostomia probably induced by this drug. Case summary We present two patients diagnosed with chronic migraine who started treatment with erenumab and presented with dry mouth after the first and second dose. What is new and conclusion Xerostomia is not described as an adverse reaction in the drug's technical datasheet. A search was made in PubMed including ‘erenumab’, ‘fremanezumab’, ‘galcanezumab’, ‘xerostomia’, and no results were found. It is necessary to identify this potential adverse reaction in order to estimate its prevalence and possible impact on patients’ quality of life. CGRP administration appears to increase blood flow in salivary glands and increase saliva production. Therefore, CGRP antagonist drugs could theoretically produce dry mouth or xerostomia.
ISSN:0269-4727
1365-2710
DOI:10.1111/jcpt.13595